SCHEDULE: Sino Lion Ventures Reports Ownership in Indaptus
Schedule 13D Amendment
Sino Lion Ventures Limited and Chenhao Xu filed an amendment to their Schedule 13D regarding their 29.19% stake in Indaptus Therapeutics, Inc.
Summary
- Sino Lion Ventures Limited and Chenhao Xu maintain beneficial ownership of 38,895,000 shares of Indaptus Therapeutics, Inc. common stock.
- The reporting persons' ownership percentage decreased to 29.19% due to an increase in the issuer's total outstanding shares following a private placement on June 17, 2026.
- The total number of outstanding shares for the issuer is reported as 133,242,324 as of June 24, 2026.
- The reporting persons did not acquire or dispose of any shares during the period covered by this amendment.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory update confirming that the reporting persons' stake remains unchanged in volume despite dilution from a recent capital raise.
Positives
- The reporting persons maintain a significant long-term equity position of 29.19% in the company.
Negatives
- The reporting persons' ownership percentage was diluted due to the company's recent private placement.
Risks
- Potential for further dilution of existing shareholders if the company continues to issue additional equity to fund operations.
Future Outlook
The filing does not provide specific forward-looking guidance regarding the company's operations, but notes the reporting persons' continued status as significant shareholders.
Management Comments
- The reporting persons confirm that they did not acquire or dispose of any shares of Common Stock in connection with the recent dilution event.
Industry Context
StockSavvy.ai notes that this filing reflects standard regulatory compliance for significant shareholders following corporate capital-raising activities in the biotechnology sector.
Comparison to Industry Standards
- The filing follows standard SEC disclosure requirements for beneficial owners holding more than 5% of a company's equity.
Stakeholder Impact
- Existing shareholders experienced dilution due to the June 17, 2026 private placement.
Next Steps
- Continued monitoring of the issuer's share count and any future changes in the reporting persons' beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 2026-03-19 | Date of the Securities Purchase Agreement. |
| 2026-03-23 | Closing date of the transaction involving Series AA and AAA Preferred Stock. |
| 2026-03-30 | Initial Schedule 13D filing date. |
| 2026-04-29 | Amendment No. 1 filed to report group disbandment. |
| 2026-06-17 | Closing date of the issuer's private placement causing dilution. |
| 2026-06-24 | Date of event requiring this filing. |
| 2026-06-26 | Date of the Joint Filing Agreement and signature date. |
Keywords
Indaptus Therapeutics, Schedule 13D, Sino Lion Ventures, Chenhao Xu, Equity Ownership, Dilution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.